Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 571

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer

Open access
Cohen, Ezra E.W., Karrison, Theodore G., Kocherginsky, Masha, Mueller, Jeffrey, Egan, Robyn, Huang, Chao H., Brockstein, Bruce E., Agulnik, Mark B., Mittal, Bharat B., Yunus, Furhan, Samant, Sandeep, Raez, Luis E., Mehra, Ranee, Kumar, Priya, Ondrey, Frank, Marchand, Patrice, Braegas, Bettina, Seiwert, Tanguy Y., Villaflor, Victoria M., Haraf, Daniel J., Vokes, Everett E.·2014·Journal of Clinical Oncology

Abstract

Purpose: Induction chemotherapy (IC) before radiotherapy lowers distant failure (DF) rates in locally advanced squamous cell carcinoma of the head and neck (SCCHN). The goal of this phase III trial was to determine whether IC before chemoradiotherapy (CRT) further improves survival compared with CRT alone in patients with N2 or N3 disease. Patients and Methods: Treatment-naive patients with nonmetastatic N2 or N3 SCCHN were randomly assigned to CRT alone (CRT arm; docetaxel, fluorouracil, and hydroxyurea plus radiotherapy 0.15 Gy twice per day every other week) versus two 21-day cycles of IC (docetaxel 75 mg/m 2 on day 1, cisplatin 75 mg/m 2 on day 1, and fluorouracil 750 mg/m 2 on days 1 to 5) followed by the same CRT regimen (IC + CRT arm). The primary end point was overall survival (OS). Secondary end points included DF-free survival, failure pattern, and recurrence-free survival (RFS). Results: A total of 285 patients were randomly assigned. The most common grade 3 to 4 toxicities during IC were febrile neutropenia (11%) and mucositis (9%); during CRT (both arms combined), they were mucositis (49%), dermatitis (21%), and leukopenia (18%). Serious adverse events were more common in the IC arm (47% v 28%; P = .002). With a minimum follow-up of 30 months, there were no statistically significant differences in OS (hazard ratio, 0.91; 95% CI, 0.59 to 1.41), RFS, or DF-free survival. Conclusion: IC did not translate into improved OS compared with CRT alone. However, the study was underpowered because it did not meet the planned accrual target, and OS was higher than predicted in both arms. IC cannot be recommended routinely in patients with N2 or N3 locally advanced SCCHN.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.54.6309

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 571

Metadata

Authors
Cohen, E. E. W., Karrison, T. G., Kocherginsky, M., Mueller, J., Egan, R., Huang, C. H., Brockstein, B. E., Agulnik, M. B., Mittal, B. B., Yunus, F., Samant, S., Raez, L. E., Mehra, R., Kumar, P., Ondrey, F., Marchand, P., Braegas, B., Seiwert, T. Y., Villaflor, V. M., Haraf, D. J., & Vokes, E. E.
Venue
Journal of Clinical Oncology
Published
2014-09-01
Volume
32
Issue
25
Pages
2735-2743
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2045248401
Cited by
571
References
23
FWCI
45.72
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. https://app.cochat.ai/papers/10.1200/jco.2013.54.6309
The paper
Cohen, E. E. W., Karrison, T. G., Kocherginsky, M., Mueller, J., Egan, R., Huang, C. H., Brockstein, B. E., Agulnik, M. B., Mittal, B. B., Yunus, F., Samant, S., Raez, L. E., Mehra, R., Kumar, P., Ondrey, F., Marchand, P., Braegas, B., Seiwert, T. Y., Villaflor, V. M., . . . Vokes, E. E. (2014). Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.54.6309

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.